This Trauma Care Chain Stock Rises 34% in 1 Year: A Rs 3,150 Crore Vote of Confidence

This trauma care chain stock has risen approximately 34% in one year, and its biggest single-day move of that period landed on 17 September 2026. The share closed at Rs 799.80 on 17 September 2025 and traded near Rs 1,070 a year later, after a record Rs 1,083.80 on volume roughly ten times normal.

The company is Yatharth Hospital and Trauma Care Services Ltd (NSE: YATHARTH), which runs nine multi-specialty hospitals in and around Delhi NCR with more than 2,800 beds. This trauma care chain stock sits among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026.

Click Here – Get Free Investment Predictions

How Much Has This Trauma Care Chain Stock Returned in 1 Year?

This trauma care chain stock returned approximately 34% over the twelve months to 17 September 2026, measured close to close. The path was not smooth. The Yatharth Hospital share price fell through the winter, bottomed at Rs 538.25 in late January 2026, then almost doubled from there. Shorter windows look far stronger than the full year.

Period	Base Date	Return
1 Month	17 Aug 2026	Up approximately 27%
6 Months	17 Mar 2026	Up approximately 63%
1 Year	17 Sep 2025	Up approximately 34%
3 Years	18 Sep 2023	Up approximately 182%
Since IPO	IPO price Rs 300	Up approximately 257%

Returns are simple price changes, and the 3-year base is 18 September 2023 because 17 September 2023 fell on a Sunday. No 5-year figure exists for this trauma care chain stock, which listed on 7 August 2023 with no split or bonus since.

Why Did This Trauma Care Chain Stock Rise 34%?

Four dated events drove this trauma care chain stock: a Rs 3,150 crore private equity investment approved on 17 September 2026, record June quarter numbers on 10 August 2026, bed acquisitions in Faridabad, Gurugram and Noida, and takeover reports on 28 August 2026.

1. Rs 3,150 Crore From Advent International, Approved 17 September 2026

The board approved a preferential issue to Rasmalai Limited, a Cyprus incorporated Advent International affiliate, on the morning of 17 September 2026. It covers 1,30,26,516 equity shares worth Rs 1,283.33 crore plus 1,89,47,664 warrants worth Rs 1,866.67 crore, all at Rs 985.17 per instrument.

On full conversion the investor holds 24.87% fully diluted and ranks as a public shareholder, so no open offer is triggered. The deal needs shareholder and regulatory clearance. That Rs 985.17 price sits below where the trauma care chain stock traded after the news.

2. Record Q1 FY27 Results and a Maiden Dividend on 10 August 2026

Yatharth Hospital reported the June 2026 quarter on 10 August 2026. Revenue was Rs 397.00 crore against Rs 267.08 crore, up approximately 49%, net profit rose about 8% to Rs 45.42 crore, and the board declared a first ever interim dividend.

Operating metrics improved with it for this trauma care chain stock. Occupancy reached 68%, up seven percentage points, average revenue per occupied bed rose about 7% to Rs 34,758, and average stay fell to 3.73 days.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	Change
Revenue	Rs 397.00 Cr	Rs 267.08 Cr	Up approximately 49%
EBITDA	Rs 96.04 Cr	Rs 73.80 Cr	Up approximately 30%
Operating Margin	24.46%	28.63%	Down 417 bps
Net Profit	Rs 45.42 Cr	Rs 42.04 Cr	Up approximately 8%

Management said the reported EBITDA margin of 23.3% would have been approximately 28.1% excluding ramp-up losses at new hospitals, and guided for FY27 growth above the 37% delivered in FY26. That is the floor under this trauma care chain stock.

3. Bed Additions in Faridabad, Noida and Gurugram

Bed count is the real engine behind this trauma care chain stock. It bought 60% of a 400-bed Faridabad facility for Rs 91.20 crore in October 2024 and put another Rs 100 crore into oncology and robotic surgery equipment. That unit hit EBITDA breakeven in nine months.

On 13 May 2026 it agreed to buy a 250-bed under construction hospital in Sector 40, Gurugram for approximately Rs 100 crore, plus Rs 100 crore to finish and equip it. Another 450 beds are planned through brownfield expansion in Noida and Noida Extension, where premium units already bill near Rs 50,000 per occupied bed.

Capacity has gone from 864 beds in FY21 to more than 2,800 now, with a pipeline near 3,250 and an ambition of about 5,000 within three years. That arithmetic is what buyers of this trauma care chain stock are paying for.

4. Stake Sale Reports From 28 August 2026

On 28 August 2026 reports said Advent International and an Aster backed platform were in talks for a controlling stake, which both denied as a concluded deal. The Yatharth Hospital share price still rallied close to 6% to a then record Rs 1,024.95, and September confirmed part of it as a minority investment.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Yatharth Hospital Financials Behind the Trauma Care Chain Stock

Revenue in this trauma care chain stock has compounded quickly while margins drifted down, the normal signature of a hospital chain in build-out mode. FY26 revenue of approximately Rs 1,233 crore was up about 37%, and net profit of approximately Rs 171 crore rose roughly 31%.

Financial Year	Revenue (Rs Cr)	EBITDA (Rs Cr)	Operating Margin	Net Profit (Rs Cr)
FY23	523.10	136.57	26.52%	65.77
FY24	686.16	195.55	29.47%	114.47
FY25	896.66	236.42	27.42%	130.55
FY26	1,232.96	316.90	Approximately 25.7%	171.07

Operating margin has slipped from 29.47% in FY24 to roughly 25.7% in FY26 and 24.46% last quarter. New hospitals lose money at first, so the dip is explainable, but it is the number to watch in this trauma care chain stock.

The balance sheet is the strong point. Debt to equity fell from 3.05 in FY21 to approximately 0.15 now, book value per share is Rs 184.79 and return on equity 9.85%. FY25 capital expenditure of Rs 310.83 crore against operating cash flow of Rs 149.60 crore explains the need for outside capital.

Who Owns This Trauma Care Chain Stock?

Promoters hold 55.80% as of June 2026, down from 61.64% a year earlier, all of it from one block deal on 28 November 2025. Promoter Neena Tyagi sold 56.33 lakh shares at Rs 716.98 for Rs 403.93 crore, and the Yatharth Hospital share price fell 8.32% that session to Rs 707.80.

Shareholder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	61.64%	61.64%	55.80%	55.80%	55.80%
FIIs	4.34%	6.50%	6.18%	5.25%	5.62%
DIIs	13.52%	8.70%	11.01%	12.00%	10.84%
Public	20.50%	23.16%	27.01%	26.95%	27.74%

Domestic institutions have been the steadier buyers, with a multi-cap fund at 5.00% and a small-cap fund at 4.24% in June 2026. If the issue completes, promoter holding in this trauma care chain stock falls well below 55.80%.

Key Risks in This Trauma Care Chain Stock

Valuation comes first. At approximately Rs 1,070 this trauma care chain stock trades at roughly 59 times trailing earnings per share of Rs 18.11 and about 5.8 times book value, on return on equity of only 9.85%. The price assumes years of clean execution.

Deal completion risk: the Rs 3,150 crore preferential issue behind this trauma care chain stock is a board approval, not a closed transaction. If it lapses, the reason for the 17 September jump in this trauma care chain stock goes with it.

Dilution: on full issue of the 3.19 crore shares and warrants, holders of this trauma care chain stock give up close to a quarter of the enlarged capital, so earnings per share will lag revenue growth until that money fills beds.

Ramp-up and margin risk: margins have fallen two years running, Gurugram is still under construction and the Noida brownfield beds are not live. A slower ramp than the nine months achieved at Faridabad would hit FY28 earnings for this trauma care chain stock.

Concentration: ownership of this trauma care chain stock sits with one family and the hospitals sit in Delhi NCR plus Jhansi, Orchha and Agra. A promoter sold 5.8% in one block in November 2025 and the share lost more than 8% that day, so insider supply is a live risk.

Liquidity and volatility: market capitalisation is approximately Rs 10,300 crore, and the Yatharth Hospital share price has swung from Rs 538.25 to Rs 1,083.80 inside twelve months. Volumes are thin on quiet days and spike on news, which widens spreads. No promoter pledge or surveillance flag turned up in public records, but position sizing in a trauma care chain stock this volatile matters.

Regulation: tariffs, implant price caps and reimbursement rules are set outside the company, and any tightening squeezes revenue per occupied bed in this trauma care chain stock directly.

Download the Univest iOS App or Univest Android App to track the Yatharth Hospital share price live

Yatharth Hospital Share: Analyst View

Analyst opinion has been constructive through 2026, built on capacity addition rather than same-store growth. A domestic brokerage writing after the 17 September announcement models revenue, EBITDA and profit compounding at 37% to 39% a year through FY29 and keeps a buy rating on this trauma care chain stock.

The bull case rests on occupancy climbing from 68% towards the 75% plus levels larger chains run, realisation moving from Rs 34,758 towards Rs 50,000, and new beds breaking even fast. The bear case for this trauma care chain stock is that margins keep falling while the multiple expands.

Yatharth Hospital Share Price Target

The latest Yatharth Hospital share price target from a domestic brokerage is Rs 1,100, set on 17 September 2026 at about 20 times FY28 estimated enterprise value to EBITDA. Against roughly Rs 1,070 that leaves around 3% upside, so this trauma care chain stock has caught up with the published number.

Parameter	Figure
Price (17 Sep 2026)	Approximately Rs 1,070
Brokerage Target (Sep 2026)	Rs 1,100
Preferential Issue Price	Rs 985.17
52-Week Range	Rs 538.25 to Rs 1,083.80

Any such target rests on assumptions about beds, occupancy and margins, not a promise. The next leg for this trauma care chain stock depends on FY28 estimates being revised upward once the raise closes.

Other Stocks to Track From the Same Return Screen

Beyond this trauma care chain stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Novartis India with a 1-year return of 126.70%, Shilpa Medicare at 125.18% and Bajaj Consumer Care at 119.43%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this trauma care chain stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This trauma care chain stock earned its 34% year the hard way, giving up a third of its value between September 2025 and January 2026 before doubling off Rs 538.25. The Rs 3,150 crore commitment at Rs 985.17 per instrument is an outside investor funding the bed plan with real money.

The counterweights are real. Operating margin fell from 29.47% in FY24 to 24.46% last quarter and the share trades near 59 times trailing earnings. Anyone buying a trauma care chain stock at a record high may prefer staggered entries, a stop loss and a word with a SEBI-registered adviser.

Frequently Asked Questions

Which trauma care chain stock rose 34% in 1 year?

Ans. Yatharth Hospital and Trauma Care Services Ltd (NSE: YATHARTH) is the trauma care chain stock that gained approximately 34% in one year, from a close of Rs 799.80 on 17 September 2025 to about Rs 1,070 on 17 September 2026, after a record Rs 1,083.80.

Why did Yatharth Hospital share price hit a record high on 17 September 2026?

Ans. The board approved a Rs 3,150 crore preferential issue to Rasmalai Limited, an Advent International affiliate, that morning. The Yatharth Hospital share price jumped almost 9% to Rs 1,083.80 on volume roughly ten times its recent average.

What are the terms of the Advent International investment?

Ans. The affiliate subscribes to 1,30,26,516 equity shares worth Rs 1,283.33 crore and 1,89,47,664 warrants worth Rs 1,866.67 crore at Rs 985.17 each. That is 24.87% fully diluted, classified as public shareholding, and it still needs shareholder and regulatory approval.

What were Yatharth Hospital Q1 FY27 results?

Ans. June 2026 quarter revenue was Rs 397.00 crore against Rs 267.08 crore, up approximately 49%. Net profit rose about 8% to Rs 45.42 crore, EBITDA was Rs 96.04 crore, occupancy reached 68% and the board declared a maiden interim dividend.

What is the Yatharth Hospital share price target?

Ans. The latest Yatharth Hospital share price target from a domestic brokerage is Rs 1,100, set on 17 September 2026 on about 20 times FY28 estimated enterprise value to EBITDA. That is roughly 3% above the current price, and an earlier Rs 920 target has been passed.

How many beds does Yatharth Hospital operate?

Ans. It runs nine multi-specialty hospitals with more than 2,800 operational beds, up from 864 in FY21. Announced capacity is around 3,250 beds, with 250 more in Gurugram and roughly 450 from brownfield expansion in Noida, against an ambition of about 5,000 in three years.

Is this trauma care chain stock expensive at these levels?

Ans. At approximately Rs 1,070 it trades at roughly 59 times trailing earnings per share of Rs 18.11 and about 5.8 times book value of Rs 184.79, while return on equity is 9.85%. The sector multiple is near 67, so this trauma care chain stock is not an outlier, but it prices in years of bed additions.

What are the main risks in this trauma care chain stock?

Ans. The largest risks in this trauma care chain stock are deal completion and dilution from the Rs 3,150 crore issue, operating margin falling from 29.47% in FY24 to 24.46% last quarter, ramp-up losses at new hospitals, and small-cap liquidity.